Independent directory Public ClinicalTrials.gov records United States
Location Directory

Clinical trials in Minneapolis, Minnesota

This page shows live ClinicalTrials.gov search results for Minneapolis, Minnesota, with direct links to official study records plus on-page filtering and sorting for broad location searches.

ClinicalTrials.gov public records Last synced Nov 19, 2026, 3:16 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Official matching trials
7879
Shown on this page
12
Current sort
Recently updated
Location scope
Minneapolis, MN
Filters apply within this location only.

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

Filter and sort this location

These controls apply only within Minneapolis, Minnesota. Default order is Recently updated. Use recruitment status if you want to focus on actively recruiting studies in this location.

Reset location filters
Clear filters
Showing 1045–1056 of 7,879 matching trials in Minneapolis, MN.
Live ClinicalTrials.gov results.
Local directory summary panels are hidden while filters are applied so the page stays focused on the filtered live results.

Live official records

Open in full search
Conditions
Recurrent Clostridioides Difficile Infection, Colonic Surgery
Interventions
Orally administered preparation of fecal microbiota (MTP-101P)
Drug
Lead sponsor
University of Minnesota
Other
Eligibility
18 Years to 75 Years
Enrollment
21 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2026
U.S. locations
1
States / cities
Minneapolis, Minnesota
Recruiting Not applicable Interventional Accepts healthy volunteers

Vaped Phenanthrene

NCT07134426
Conditions
Former Smoker, Non-Smoker
Interventions
D10-phenanthrene
Other
Lead sponsor
University of Minnesota
Other
Eligibility
21 Years and older
Enrollment
100 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026 – 2028
U.S. locations
1
States / cities
Minneapolis, Minnesota
Active, not recruiting Not applicable Interventional

Evaluation of an Explicit Approach

NCT04902508
Conditions
Developmental Language Disorder, Explicit Intervention, Grammatical Language
Interventions
Implicit-only, Explicit-added
Behavioral
Lead sponsor
University of Minnesota
Other
Eligibility
5 Years to 9 Years
Enrollment
111 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2027
U.S. locations
1
States / cities
Minneapolis, Minnesota
Conditions
Neoplasms
Interventions
Letetresgene autoleucel, Cyclophosphamide, Fludarabine
Drug
Lead sponsor
USWM, LLC (dba US WorldMeds)
Industry
Eligibility
10 Years and older
Enrollment
7 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2026
U.S. locations
24
States / cities
Duarte, California • Stanford, California • Denver, Colorado + 19 more
Conditions
Scleroderma, Diffuse
Interventions
rapcabtagene autoleucel, rituximab
Biological
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years to 70 Years
Enrollment
96 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2032
U.S. locations
13
States / cities
Los Angeles, California • San Francisco, California • San Pablo, California + 10 more
Conditions
Resectable Lung Non-Small Cell Carcinoma, Stage II Lung Cancer AJCC v8, Stage IIIA Lung Cancer AJCC v8, Stage IIIB Lung Cancer AJCC v8
Interventions
Surgical Procedure, Cisplatin, Carboplatin, Pemetrexed, Gemcitabine, Docetaxel, Vinorelbine, Nivolumab, Pembrolizumab, Atezolizumab, Computed Tomography, Magnetic Resonance Imaging, Positron Emission Tomography
Procedure · Drug
Lead sponsor
Alliance for Clinical Trials in Oncology
Other
Eligibility
18 Years and older
Enrollment
37 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2030
U.S. locations
415
States / cities
Birmingham, Alabama • Fairbanks, Alaska • Phoenix, Arizona + 319 more
Conditions
Migraine
Interventions
Lasmiditan, Placebo
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
6 Years to 17 Years
Enrollment
847 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2025
U.S. locations
77
States / cities
Birmingham, Alabama • Huntsville, Alabama • Phoenix, Arizona + 68 more
Conditions
Diabetes Mellitus, Type 1
Interventions
Abrocitinib 200 MG Oral Tablet, Ritlecitinib, Placebo
Drug
Lead sponsor
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
NIH
Eligibility
12 Years to 35 Years
Enrollment
78 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2027
U.S. locations
23
States / cities
Orange, California • Palo Alto, California • San Francisco, California + 20 more
Conditions
Type 1 Diabetes Mellitus, Type 2 Diabetes Mellitus
Interventions
MiniMed™ NMX8-AID System with DS5™/Simplera Sync™
Device
Lead sponsor
Medtronic MiniMed, Inc.
Industry
Eligibility
7 Years to 85 Years
Enrollment
389 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
29
States / cities
Little Rock, Arkansas • Escondido, California • Goleta, California + 25 more
Conditions
Cancer, HPV Associated Cancer
Interventions
GLAm app
Behavioral
Lead sponsor
Masonic Cancer Center, University of Minnesota
Other
Eligibility
9 Years to 26 Years
Enrollment
162 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2026
U.S. locations
1
States / cities
Minneapolis, Minnesota
Conditions
Low Grade Glioma
Interventions
Carboplatin and Vincristine, Carboplatin
Drug
Lead sponsor
Alicia Lenzen
Other
Eligibility
Up to 21 Years
Enrollment
95 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2025
U.S. locations
21
States / cities
Phoeniz, Arizona • San Diego, California • New Haven, Connecticut + 17 more
Conditions
Non-Small Cell Lung Cancer, Colorectal Cancer, Breast Cancer, Ovarian Cancer, Endometrial Carcinoma, Head and Neck Squamous Cell Carcinoma
Interventions
FT836, Cetuximab, Trastuzumab
Drug
Lead sponsor
Fate Therapeutics
Industry
Eligibility
18 Years and older
Enrollment
119 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2030
U.S. locations
5
States / cities
La Jolla, California • Los Angeles, California • Minneapolis, Minnesota + 2 more